Hip fracture
Conditions
Interventions
Group Tegileridine:During induction of anesthesia, select sufentanil 0.3–0.4 µg/kg as the opioid analgesic, etomidate 0.3 mg/kg as the sedative, and rocuronium bromide 0.6 mg/kg as the muscle relaxant
propofol is discontinued approximately 10 minutes before surgery completion, with an additional bolus of 0.05 µg/kg sufentanil
remifentanil is discontinued immediately upon surgery completion. Postoperative analgesia commenced with an intravenous loading dose of 0.5 mg (2 mL) of tegilerdine. Following the loading dose, 48-hou
Group Sufentanil:During induction of anesthesia, select sufentanil 0.3–0.4 µg/kg as the opioid analgesic, etomidate 0.3 mg/kg as the sedative, and rocuronium bromide 0.6 mg/kg as the muscle relaxant.
Sponsors
Huaihe Hospital of Henan University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age over 65 years old; 2. Patients scheduled for total hip replacement under general anesthesia; 3. ASA classification Grade II or III; 4. BMI 18 to 30 kg^2; 5. Able to comprehend methods for assessing pain intensity.
Exclusion criteria
Exclusion criteria: 1. Pre-existing acute or chronic pain; 2. Advanced tumors with ascites or widespread metastasis, or currently undergoing systemic chemotherapy or radiotherapy, or requiring postoperative hyperthermic perfusion; 3. Allergic to or contraindicated for anesthetics, adjuvant analgesics, rescue analgesics, antiemetics, or antibiotics used in the study; 4. Long-term treatment with opioids or use of any analgesic within 48 hours before surgery; 5. Suffering from sleep apnea syndrome; 6. Suffering from mental and neurological diseases, gastrointestinal obstruction, chronic obstructive pulmonary disease or cor pulmonale, cardiovascular diseases, etc.; 7. Oral, inhalational, or parenteral administration of corticosteroids within three months before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate to the test drug at various time points within 24 hours after administration of the loading dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients not administered rescue analgesic medication during the treatment period;Number of supplementary analgesic administrations during the treatment period;Total number of compressions and effective compressions for the PCIA pump;Frequency of use of rescue analgesics during the treatment period; | — |
Countries
China
Contacts
Public ContactXin Wenqi
Huaihe Hospital of Henan University
Outcome results
None listed